Abstract
Background
Sub-Saharan African countries have a high burden of viral hepatitis and poor access to screening and care. The aim of this study was to evaluate the feasibility and acceptability of using the plasma separation card (PSC) for viral hepatitis B and C screening among people living with HIV (PLHIV) in Cameroon and Uganda.
Methods
This is a cross-sectional study carried out between 05/2021 and 03/2023 including 192 PLHIV in Cameroon (n = 104) and Uganda (n = 88). Basic sociodemographic variables and whole blood samples were collected. Adequate filling with blood of PSCs was used to determine feasibility together with participant responses to questions on acceptability. A logistic regression model was carried out to assess the relationship between PSC acceptability and factors of interest.
Results
70% of participants reported PSC as an acceptable viral hepatitis screening tool, and it was significantly more accepted in Uganda than Cameroon (100% vs. 43.2%, p < 0.001). Similarly, 75% of PSCs had at least one spot sample filled and were viable for analysis, 99% were correctly filled in Uganda and 53.4% in Cameroon. Reported ease of method performance (aOR: 24.77 95% CI 2.97-206.42, p = 0.003) and reduced collection time (aOR: 3.73 95% CI 1.26–11.04, p = 0.017) were associated with greater odds of PSC acceptance. HBsAg + and anti-HCV + prevalence were 11.1% and 1.0%, respectively.
Conclusions
In spite of country differences, overall, the PSC was reported as a feasible and acceptable viral hepatitis testing method. Acceptability and feasibility of the method must be explored in heterogeneous target communities and qualitative research to better understand country-specific barriers and facilitators should be carried out.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Nicolàs, Aina 1
; Ayemfouo Fofou, Ironne Valdèse 2 ; Kasone, Viola 3 ; Guewo-Fokeng, Magellan 2 ; Tagny, Claude T 4
; Nanyonjo, Teddy 3 ; Nansumba, Hellen 3
; Kouongni, Yves Nacel 4 ; Sezawo Kamdjeu, Rita Gaëlle Epse 4 ; Seremba, Emmanuel 5 ; Kouanfack, Charles 6 ; Ssewanyana, Isaac 3 ; Njouom, Richard 7
; Segura, Ariadna Rando 8 ; Rodríguez-Frías, Francisco 9 ; Mbanya, Jean Claude 10
; Ocama, Ponsiano 11
; Lazarus, Jeffrey V. 12
1 Hospital Clínic, University of Barcelona, Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413)
2 University of Yaoundé I, Department of Biochemistry, Faculty of Science, Yaoundé, Cameroon (GRID:grid.412661.6) (ISNI:0000 0001 2173 8504); University of Yaoundé I, Laboratory of Molecular Medicine and Metabolism, Biotechnology Centre, Yaoundé, Cameroon (GRID:grid.412661.6) (ISNI:0000 0001 2173 8504)
3 Central Public Health Laboratories, Ministry of Health of Uganda, Kampala, Uganda (GRID:grid.415705.2)
4 University Teaching Hospital of Yaoundé, Hematology and Blood Transfusion Unit, Yaoundé, Cameroon (GRID:grid.449865.2)
5 Kiruddu National Referral Hospital, Kampala, Uganda (GRID:grid.513250.0)
6 Yaoundé Central Hospital, Day Hospital, HIV Care and Treatment Unit, Yaoundé, Cameroon (GRID:grid.460723.4) (ISNI:0000 0004 0647 4688); University of Dschang, Department of Public Health, Faculty of Medicine and Pharmaceutical Sciences, Dschang, Cameroon (GRID:grid.8201.b) (ISNI:0000 0001 0657 2358)
7 Centre Pasteur of Cameroon, Yaoundé, Cameroon (GRID:grid.418179.2)
8 Vall d’Hebron Hospital Universitari, Department of Microbiology, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654); CIBEREHD Instituto de Salud Carlos III, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
9 Vall d’Hebron Institut de Recerca (VHIR), Liver Pathology Unit, Department of Biochemistry, Barcelona, Spain (GRID:grid.430994.3) (ISNI:0000 0004 1763 0287)
10 University of Yaoundé I, Laboratory of Molecular Medicine and Metabolism, Biotechnology Centre, Yaoundé, Cameroon (GRID:grid.412661.6) (ISNI:0000 0001 2173 8504); University of Yaoundé I, Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, Yaoundé, Cameroon (GRID:grid.412661.6) (ISNI:0000 0001 2173 8504); National Obesity Centre, University of Yaoundé I, Yaoundé Central Hospital, Yaoundé, Cameroon (GRID:grid.412661.6) (ISNI:0000 0001 2173 8504)
11 Makerere University, College of Health Sciences, Kampala, Uganda (GRID:grid.11194.3c) (ISNI:0000 0004 0620 0548)
12 Hospital Clínic, University of Barcelona, Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413); City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), New York, USA (GRID:grid.212340.6) (ISNI:0000 0001 2298 5718); University of Barcelona, Faculty of Medicine, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)





